Display options
Cite
Doss RW, El-Rifaie AA, Abdel-Wahab AM, et al. Heat Shock Protein-70 Expression in Vitiligo and its Relation to the Disease Activity. Indian J Dermatol. 2016;61(4):408-12doi: 10.4103/0019-5154.185704.
Doss, R. W., El-Rifaie, A. A., Abdel-Wahab, A. M., Gohary, Y. M., & Rashed, L. A. (2016). Heat Shock Protein-70 Expression in Vitiligo and its Relation to the Disease Activity. Indian journal of dermatology, 61(4), 408-12. https://doi.org/10.4103/0019-5154.185704
Doss, Reham William, et al. "Heat Shock Protein-70 Expression in Vitiligo and its Relation to the Disease Activity." Indian journal of dermatology vol. 61,4 (2016): 408-12. doi: https://doi.org/10.4103/0019-5154.185704
Doss RW, El-Rifaie AA, Abdel-Wahab AM, Gohary YM, Rashed LA. Heat Shock Protein-70 Expression in Vitiligo and its Relation to the Disease Activity. Indian J Dermatol. 2016 Jul-Aug;61(4):408-12. doi: 10.4103/0019-5154.185704. PMID: 27512186; PMCID: PMC4966399.
Copy Download .nbib Format: NLM
Share it on

Indian J Dermatol. 2016 Jul-Aug;61(4):408-12. doi: 10.4103/0019-5154.185704.

Heat Shock Protein-70 Expression in Vitiligo and its Relation to the Disease Activity.

Indian journal of dermatology

Reham William Doss, Abdel-Aziz A El-Rifaie, Amr M Abdel-Wahab, Yasser M Gohary, Laila A Rashed

Affiliations

  1. Department of Dermatology, Faculty of Medicine, Beni-Suef University, Beni Suef, Egypt.
  2. Department of Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt.

PMID: 27512186 PMCID: PMC4966399 DOI: 10.4103/0019-5154.185704

Abstract

BACKGROUND: Vitiligo is a progressive depigmenting disorder characterized by the loss of functional melanocytes from the epidermis. The etiopathogenesis of vitiligo is still unclear. Heat shock proteins (HSPs) are prime candidates to connect stress to the skin. HSPs were found to be implicated in autoimmune diseases such as rheumatoid arthritis and other skin disorders as psoriasis.

AIM AND OBJECTIVES: The aim of this study was to map the level of HSP-70 in vitiligo lesions to declare its role in the pathogenesis and activity of vitiligo.

MATERIALS AND METHODS: The study included thirty patients with vitiligo and 30 age- and sex-matched healthy controls. Vitiligo patients were divided as regards to the disease activity into highly active, moderately active, and inactive vitiligo groups. Skin biopsies were taken from the lesional and nonlesional skin of patients and from the normal skin of the controls. HSP-70 messenger RNA (mRNA) expression was estimated using quantitative real-time polymerase chain reaction.

RESULTS: Our analysis revealed a significantly higher expression of HSP-70 mRNA in lesional skin biopsies from vitiligo patients compared to nonlesional skin biopsies from vitiligo patients (P < 0.001) and compared to skin biopsies from healthy controls (P < 0.001). The level of HSP-70 was not found to be correlated with age, sex, or disease duration. The expression of HSP-70 was correlated with the disease activity and patients with active vitiligo showed higher mean HSP-70 level compared to those with inactive disease.

CONCLUSIONS: HSP-70 plays a role in the pathogenesis of vitiligo and may enhance the immune response in active disease.

Keywords: Heat shock protein-70; messenger RNA; real-time polymerase chain reaction; vitiligo

References

  1. Pigment Cell Melanoma Res. 2014 Mar;27(2):209-20 - PubMed
  2. J Invest Dermatol. 1999 Nov;113(5):725-31 - PubMed
  3. Exp Oncol. 2012 Oct;34(3):286-97 - PubMed
  4. Pigment Cell Melanoma Res. 2012 Jan;25(1):88-98 - PubMed
  5. Methods. 2001 Dec;25(4):402-8 - PubMed
  6. Exp Dermatol. 2011 Jan;20(1):35-40 - PubMed
  7. J Invest Dermatol. 1991 Sep;97(3):395-404 - PubMed
  8. J Eur Acad Dermatol Venereol. 2011 Jul;25(7):749-57 - PubMed
  9. J Biosci. 2007 Apr;32(3):579-84 - PubMed
  10. Cold Spring Harb Perspect Biol. 2013 Mar 01;5(3):a013169 - PubMed
  11. Ann Diagn Pathol. 2013 Jun;17(3):245-9 - PubMed
  12. Am J Pathol. 1996 Apr;148(4):1219-28 - PubMed
  13. Curr Dir Autoimmun. 2008;10:227-43 - PubMed
  14. J Eur Acad Dermatol Venereol. 2012 Jul;26(7):861-7 - PubMed
  15. Br J Dermatol. 2012 Nov;167(5):1017-24 - PubMed
  16. J Invest Dermatol. 2009 Sep;129(9):2220-32 - PubMed
  17. Arch Dermatol. 1997 Jul;133(7):922-3. - PubMed
  18. Int J Mol Med. 2010 Jul;26(1):57-65 - PubMed
  19. Nature. 1992 Jan 2;355(6355):33-45 - PubMed
  20. Protoplasma. 2012 Jan;249(1):21-30 - PubMed
  21. BMC Immunol. 2011 Mar 28;12:24 - PubMed
  22. J Invest Dermatol. 2008 Aug;128(8):2041-8 - PubMed
  23. Cell Stress Chaperones. 1996 Apr;1(1):23-8 - PubMed
  24. Semin Cell Dev Biol. 2010 Jul;21(5):500-11 - PubMed
  25. BMC Evol Biol. 2008 Jan 23;8:19 - PubMed
  26. J Invest Dermatol. 2012 Nov;132(11):2601-9 - PubMed
  27. J Leukoc Biol. 2009 Jun;85(6):905-10 - PubMed
  28. Handb Exp Pharmacol. 2006;(172):279-304 - PubMed
  29. J Invest Dermatol. 2005 Apr;124(4):798-806 - PubMed
  30. N Engl J Med. 2010 May 6;362(18):1686-97 - PubMed
  31. Expert Rev Vaccines. 2008 Sep;7(7):1019-30 - PubMed

Publication Types